News
Ashvattha Therapeutics Subsidiary Orpheris Announces Completion of Phase 1 Study of OP-101 Subcutaneous Formulation June 10, 2020 08:00 AM Eastern Daylight Time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback